P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
Joseph Mikhael,Paul G. Richardson,Saad Z. Usmani,Noopur Raje,William I. Bensinger,Chatchada Karanes,Frank Campana,Dheepak Kanagavel,Franck Dubin,Qianying Liu,Dorothée Semiond,Kenneth C. Anderson +11 more
TL;DR: Overall response rate was 62%; median duration of response was 18.7 months; median progression-free survival was 17.6 months; and the 10 mg/kg QW/Q2W isatuximab dose was selected for future studies, demonstrating potential meaningful clinical activity and a manageable safety profile.
Journal ArticleDOI
Drug safety evaluation of defibrotide.
Paul G. Richardson,Selim Corbacioglu,Vincent T. Ho,Nancy A. Kernan,Leslie Lehmann,Craig Maguire,Michelle E. Maglio,Margaret Hoyle,Marco Sardella,Sergio Giralt,Ernst Holler,Enric Carreras,Dietger Niederwieser,Robert J. Soiffer +13 more
TL;DR: Current clinical findings on DF are reviewed, primarily in terms of safety for use in treatment and prophylaxis of VOD, and relevant safety data for its use in other diseases are reviewed.
Journal ArticleDOI
Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review.
Weijuan Li,David A. Garcia,R. Frank Cornell,David Gailani,Jacob P. Laubach,Michelle E. Maglio,Paul G. Richardson,Javid Moslehi +7 more
TL;DR: It is concluded that more research is needed for better screening and preventive strategies to abrogate these toxic effects of multiple myeloma's toxic effects and improve patient care.
Journal ArticleDOI
Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)
Philippe Moreau,Tamas Masszi,Norbert Grzasko,Nizar J. Bahlis,Markus Hansson,Ludek Pour,Irwindeep Sandhu,Peter Ganly,Bartrum W Baker,Sharon Jackson,Anne-Marie Stoppa,D. Simpson,Peter Gimsing,Antonio Palumbo,Laurent Garderet,Michele Cavo,Shaji Kumar,Cyrille Touzeau,Francis K. Buadi,Jacob P. Laubach,Jianchang Lin,Deborah Berg,Alessandra DiBacco,Ai-Min Hui,Paul G. Richardson +24 more
TL;DR: The study met the primary endpoint at the first IA, demonstrating a 35% improvement in PFS with IRd vs Rd, and met the final analysis for PFS, indicating ixazomib may overcome the negative impact of cytogenetic alterations.
Journal ArticleDOI
Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.
Edwin P. Alyea,Edwin P. Alyea,Edie Weller,Robert L. Schlossman,Robert L. Schlossman,Christine Canning,Christine Canning,Peter Mauch,Andrea K. Ng,David E. Fisher,David E. Fisher,John G. Gribben,John G. Gribben,Andrea Freeman,Andrea Freeman,Bijal Parikh,Bijal Parikh,Paul G. Richardson,Paul G. Richardson,Robert J. Soiffer,Robert J. Soiffer,Jerome Ritz,Jerome Ritz,KC Anderson,KC Anderson +24 more
TL;DR: Autologous transplantation is associated with improved OS and PFS compared with allogeneic transplantation in patients with MM, and strategies focused on reducing nonrelapse mortality in allogenei transplantation may translate into an improved outcome for patients receiving allogeneIC transplantation.